RISING TIDES
Observations from the IMC Research Process

Merck and Moderna’s mRNA Milestone

A personalized cancer vaccine just cleared a major clinical hurdle, opening the door to a much broader opportunity.

• From promise to proof. Merck ($MRK) and Moderna ($MRNA) have combined Keytruda with a personalized mRNA vaccine built around the mutations in each patient’s tumor. Positive Phase 3 melanoma results validate a model where treatment is designed around the biology of the individual patient, with the platform already being evaluated across eight additional solid-tumor programs.
• Precision medicine on the front burner. Falling sequencing costs and advances in mRNA, cell therapy, and molecular diagnostics are creating a new treatment loop: sequence, target, treat, measure, adapt. Molecular residual disease testing can detect recurrence earlier and help physicians adjust treatment based on a patient’s molecular response.
• The opportunity is broader than one vaccine. Merck and Moderna own the newly validated cancer-vaccine platform; Illumina ($ILMN) enables sequencing; Natera ($NTRA) and Tempus AI ($TEM) power testing and monitoring; and Labcorp ($LH) and Quest Diagnostics ($DGX) provide scaled specialty-testing infrastructure. Iovance ($IOVA) already commercializes individualized cell therapy, while Maravai ($MRVI) and Repligen ($RGEN) provide critical inputs and manufacturing technologies behind increasingly personalized treatments.